Hazard Hub
New safety information Recalls in Canada — Page 2
38 recalls involving new safety information — most are other recalls. Newest first, updated daily from government open data.
Showing 31–38 of 38
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
New safety information - Product safety
View recall details →
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
New safety information - COVID
View recall details →
COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine): New Formulation for Use in Children Aged 5 Years to Less Than 12 Years
New safety information - Packaging - Supply
View recall details →
Health Canada clarifies position on Platelet Rich Plasma treatments
New safety information
View recall details →
Important Safety Information on Alaris Infusion Sets and Alaris 8100 Pump Module - Risk of Over-Infusion
New safety information - Medical devices
View recall details →
Talc - Potential Risk of Lung Effects and Ovarian Cancer
New safety information
View recall details →
Tromboject 1% and 3% (sodium tetradecyl sulfate) with Visible Particles - Update on the Use of Medical Grade Filters
New safety information
View recall details →
Health Canada updates Canadians on estimates of health risks for recalled valsartan drugs containing NDMA
New safety information
View recall details →